Uncategorized

A Wegovy weight loss pill from Novo Nordisk is forthcoming, providing an alternative to injectable GLP-1 drugs. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight loss medication Wegovy. Experts say an oral medication might be easier for people to use, […]

(MedPage Today) — GLP-1 receptor agonists for patients with diabetes was not associated with an increased risk for acute pancreatitis, a multicenter analysis found. (American Journal of Gastroenterology) Allogeneic hematopoietic stem cell transplant…

THURSDAY, May 15, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity, according to a study published online May 11 in…

Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s clinical trial data, presented May 12 at the European Congress on Obesity. Here are three notes from the secondary analysis: The “Semaglutide and Cardiovascular Outcomes

Physical activity is essential for body weight maintenance after body weight-loss, partly by promoting the coupling between energy intake and expenditure. However, the underlying mechanisms remain largely unknown. Here we demonstrate that running induces small intestine growth independently of GLP-2. In addition, exercise increases L-cell density in the small intestine and glucose-stimulated GLP-1 secretion, and

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still prefer to lose weight without using medications. For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

Learn about SYNT-101, the emerging treatment for obesity that combines the best of two proven methods.

Industry stakeholders can take steps to better understand the needs and preferences of GLP-1 patients who seek to address one—and often multiple—aesthetic concerns.

A new study has found GLP-1s may reduce the risk of developing obesity-related cancers by 41% compared to bariatric surgery — a benefit researchers believe could be tied to the drugs’ ability to reduce inflammation.  The findings, published May 11 in The Lancet’s eClinicalMedicine journal, are based on data from more than 6,000 adults. Researchers

For the same pharmaceutical products, US prices can be anywhere between two and ten times higher in US markets compared to prices across the border. Nor is importation allowed, even though this would drive prices toward equilibrium by facilitating market competition. This problem has persisted for decades. US taxpayers and health insurance subscribers subsidize pharmaceutical